Systematic Reviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jun 14, 2019; 25(22): 2809-2818
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2809
Table 4 Outcome definitions
Author (year)RemissionTreatment failureRelapse
Schramm et al[6], 2001IAIHG revised criteria (1999)-IAIHG revised criteria (1999)
Granito et al[21], 2005IAIHG revised criteria (1999)-IAIHG revised criteria (1999)
Al-Chalabi et al[23], 2006IAIHG revised criteria (1999)IAIHG original criteria (1993)IAIHG revised criteria (1999)
PR: IAIHG original criteria (1993)
Czaja et al[9], 2006Symptoms: AbsentWorsening of clinical, laboratory and/or histological alterations despite compliance to therapySymptom recurrence and increased serum AST level (> three-fold the ULN) after drug withdrawal
AST level: Normal or near normal (< two-fold the UNL)
Histology: Minimal/no inflammation
SR:
Symptoms: Absent
Serum AST levels: Normal or below the relapse threshold
after drug withdrawal
Zhang et al[22], 2012Symptoms: AbsentWorsening of clinical, laboratory and/or histological alterations despite compliance to therapySymptom recurrence and increased serum AST level (> three-fold the ULN) after drug withdrawal
AST levels: Normal or near normal (< two-fold the UNL)
Histology: Minimal or no inflammation.
SR:
Symptoms: Absent
AST levels: Normal or below the relapse threshold after drug withdrawal
Zachou et al[20], 2016CR:Persistently elevated AST and ALT (> three-fold the UNL) and/or increased IgG despite intensive immunosuppression and compliance to therapyRise in AST and ALT levels (> three-fold the UNL) and/or increased IgG (> 2000 mg/dL) during therapy with or without symptom recurrence after initial CR
Symptoms: Improved
AST, ALT, IgG levels: normal
Histology: Minimal/no inflammation
PR:
ALT or AST levels: Decreased (< two-fold ULN) without achieving complete normalization and inability to withdraw or taper prednisolone
Morii et al[24], 2017Normal serum ALT and IgG levels-Re-exacerbation not explicitly defined